{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    44,
    45,
    51,
    52,
    53,
    55,
    58,
    139,
    61,
    65,
    66,
    67,
    69,
    71,
    77,
    78,
    79,
    80,
    81,
    82,
    83,
    84,
    85,
    97,
    114,
    118,
    119,
    121
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "treatment start"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline assessment"
      },
      {
        "id": "anchor_5",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle \n1, Day 1"
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening period"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_6",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P28D",
        "sourceText": "28-day cycle"
      },
      {
        "id": "rep_cycle_7",
        "type": "Cycle",
        "cycleLength": "P4D",
        "sourceText": "4-week \ncycle"
      },
      {
        "id": "rep_cycle_15",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_16",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until death"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "minObservations": 1,
        "exitCondition": "Disease progression or unacceptable toxicity",
        "sourceText": "Administration of First and Subsequent Infusions of Atezolizumab/Placebo"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "End of Study",
          "Baseline Tumour Evaluation",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring permanent treatment discontinuation', 'path': ['TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'If subject consents to optional research', 'path': ['RESEARCH_BIOSAMPLE_REPOSITORY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Imaging",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 4; SINGLE signals: 3"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 6"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Informed Consent",
        "executionType": "Single",
        "rationale": "Obtained once from persons prior to drug administration as part of the screening/enrollment process."
      },
      {
        "activityId": "Serum Pharmacokinetic/Anti-drug Antibody Samples",
        "executionType": "Single",
        "rationale": "Scheduled collection at specific study visits, though discontinued at the Follow-Up visit in Version 3."
      },
      {
        "activityId": "Adverse Event Monitoring (Immune-mediated events)",
        "executionType": "Single",
        "rationale": "Continuous monitoring for potential risks and management of events throughout the treatment period."
      },
      {
        "activityId": "Cardiac Imaging (Myocarditis Assessment)",
        "executionType": "Single",
        "rationale": "Conditional activity triggered by signs or symptoms suggestive of myocarditis as per management guidelines."
      },
      {
        "activityId": "Laboratory Abnormalities (B-type natriuretic peptide)",
        "executionType": "Single",
        "rationale": "Conditional assessment used to identify signs suggestive of myocarditis within the management guidelines."
      },
      {
        "activityId": "Infusion-related Reaction Management (CRS)",
        "executionType": "Single",
        "rationale": "Conditional workflow involving definition, grading, and management steps triggered only if a reaction occurs."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "[a1] If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date.",
        "footnoteId": "fn_1",
        "sourceText": "[a1] If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "[a2] Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion.",
        "footnoteId": "fn_2",
        "sourceText": "[a2] Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "procedure_timepoints",
        "text": "[a3] Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.",
        "footnoteId": "fn_3",
        "sourceText": "[a3] Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 1"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_after",
        "text": "[b] Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.",
        "footnoteId": "fn_4",
        "sourceText": "[b] Patients will be asked to return to the clinic within 30 days after their last study drug dose f"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "[o] Serum pregnancy test within 7 days before Cycle 1, Day 1.",
        "footnoteId": "fn_5",
        "sourceText": "[o] Serum pregnancy test within 7 days before Cycle 1, Day 1."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "[p] Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
        "footnoteId": "fn_6",
        "sourceText": "[p] Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pre"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "[q] TSH, free T3 and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, and every second cycle thereafter.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.before(day 1 of cycle 1, and every second cycle thereafter., PT96M)",
        "timingConstraint": "PT96H",
        "sourceText": "[q] TSH, free T3 and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, and every sec"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_before",
        "text": "[w] Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.",
        "footnoteId": "fn_9",
        "sourceText": "[w] Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "[z] All patients will be followed for survival and new anti-cancer therapy information every 3 months ± 21 days.",
        "footnoteId": "fn_10",
        "sourceText": "[z] All patients will be followed for survival and new anti-cancer therapy information every 3 month"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "Date of randomization",
          "Date of first occurrence of disease progression (RECIST v1.1)",
          "Date of death from any cause",
          "Date of last tumor assessment"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until first occurrence of disease progression or death"
        },
        "algorithm": "min(Date of disease progression, Date of death) - Date of randomization. If no event, censor at last tumor assessment date. If no post-baseline assessment, censor at Date of randomization + 1 day.",
        "successCriteria": "Statistically significant improvement in PFS compared to placebo arm based on stratified log-rank test (alpha = 0.05) following hierarchical testing order.",
        "sourceText": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause dur"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death from any cause"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Statistically significant improvement in OS compared to placebo arm, tested hierarchically after PFS.",
        "sourceText": "overall survival (OS) in the PD-L1-positive subpopulation; [4] OS in the ITT population"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "Number of patients with objective response (CR or PR)",
          "Total number of patients in subpopulation"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Study duration"
        },
        "algorithm": "(Patients with confirmed Complete Response [CR] or Partial Response [PR]) / (Total patients in evaluable population)",
        "successCriteria": "Higher proportion of responders in atezolizumab arm compared to placebo arm.",
        "sourceText": "ORR by RECIST v1.1 in the PD-L1-positive, Response-evaluable subpopulation; [6] ORR by RECIST v1.1 in the ITT population."
      },
      {
        "id": "ep_4",
        "name": "Secondary: Time to Deterioration in Global Health Status",
        "endpointType": "Secondary",
        "inputs": [
          "Baseline Global Health Status score",
          "Post-baseline Global Health Status scores"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Study duration"
        },
        "algorithm": "Time from randomization to first decrease in Global Health Status score (threshold typically defined in SAP)",
        "successCriteria": "Delayed time to deterioration compared to placebo arm.",
        "sourceText": "Time to deterioration in Global Health Status"
      },
      {
        "id": "ep_5",
        "name": "Secondary: Clinical Benefit Rate (CBR)",
        "endpointType": "Secondary",
        "inputs": [
          "RECIST v1.1 response",
          "Duration of stable disease"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Study duration"
        },
        "algorithm": "(Patients with CR + PR + Stable Disease [SD] of specific duration) / (Total patients)",
        "successCriteria": "Higher proportion of patients with clinical benefit in treatment arm.",
        "sourceText": "Clinical Benefit Rate"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Overall Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Death",
          "Date of Randomization"
        ],
        "derivationRule": "Date of death from any cause minus date of randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until death",
        "imputationRule": "Censored at date last known to be alive",
        "unit": "Days/Months"
      },
      {
        "id": "dv_2",
        "name": "Time to deterioration in Global Health Status",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EORTC QLQ-C30 Global Health Status score",
          "Baseline Global Health Status score"
        ],
        "derivationRule": "Time from randomization to the first decrease in GHS score of at least 10 points from baseline",
        "baselineDefinition": "Last non-missing assessment prior to first dose",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until first deterioration",
        "imputationRule": "Censored at last valid PRO assessment",
        "unit": "Days/Months"
      },
      {
        "id": "dv_3",
        "name": "Progression-Free Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Disease Progression",
          "Date of Death",
          "Date of Randomization"
        ],
        "derivationRule": "Time from randomization to the first occurrence of disease progression or death from any cause",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until progression or death",
        "imputationRule": "Censored at last tumor assessment",
        "unit": "Days/Months"
      },
      {
        "id": "dv_4",
        "name": "Objective Response Rate",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best Overall Response"
        ],
        "derivationRule": "Proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR)",
        "baselineDefinition": "Presence of measurable disease at baseline",
        "baselineVisit": "Day 1",
        "analysisWindow": "Duration of study",
        "imputationRule": "Non-responders for missing data",
        "unit": "Percentage"
      },
      {
        "id": "dv_5",
        "name": "Duration of Objective Response",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of first CR or PR",
          "Date of Disease Progression",
          "Date of Death"
        ],
        "derivationRule": "Time from first documented response (CR or PR) to first documented disease progression or death",
        "baselineDefinition": "First occurrence of CR or PR",
        "baselineVisit": "Post-baseline",
        "analysisWindow": "From first response until progression or death",
        "imputationRule": "Censored at last tumor assessment",
        "unit": "Days/Months"
      },
      {
        "id": "dv_6",
        "name": "Clinical Benefit Rate",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best Overall Response",
          "Duration of Stable Disease"
        ],
        "derivationRule": "Proportion of patients with CR, PR, or Stable Disease (SD) lasting at least 6 months",
        "baselineDefinition": "Presence of measurable or evaluable disease at baseline",
        "baselineVisit": "Day 1",
        "analysisWindow": "Duration of study",
        "imputationRule": "Non-responders for missing data",
        "unit": "Percentage"
      },
      {
        "id": "dv_7",
        "name": "Changes from Baseline in Patient Function and Symptoms",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "EORTC QLQ-C30 scores",
          "QLQ-BR23 scores"
        ],
        "derivationRule": "Post-baseline score - Baseline score",
        "baselineDefinition": "Last non-missing assessment prior to first dose",
        "baselineVisit": "Day 1",
        "analysisWindow": "Scheduled PRO assessment timepoints",
        "imputationRule": "MMRM or as specified in the SAP",
        "unit": "Score points"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Treatment",
        "Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Treatment": "TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Appendix",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 9.0,
            "unit": "g"
          }
        ],
        "sourceText": "Status Scale .............................................................................. 174 Appendix 8 Cockcroft-Gault formula ............................................................ 175 Appe"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Version",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "g"
          }
        ],
        "sourceText": "bilirubin ≤ 1.25× ULN Patients with known Gilbert’s disease who have serum bilirubin level ≤ 3× ULN may be enrolled. Atezolizumab—F. Hoffmann-La Roche Ltd 24/Protocol MO39196 (IMpassion131), Version 6"
      },
      {
        "id": "dosing_3",
        "treatmentName": "Type",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "g"
          }
        ],
        "sourceText": "medicinal products (IMPs) in this study. All IMPs will be supplied by the Sponsor. Atezolizumab (Investigational Drug) The atezolizumab drug product is provided in a single-use, 20cc USP/Ph. Eur. Type"
      },
      {
        "id": "dosing_4",
        "treatmentName": "Diphenhydramine",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 300.0,
            "unit": "mg"
          }
        ],
        "sourceText": "6 hours prior to the paclitaxel infusion Patients may be treated with dexamethasone ≤10 mg IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. • Diphe"
      },
      {
        "id": "dosing_5",
        "treatmentName": "Cimetidine",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 300.0,
            "unit": "mg"
          },
          {
            "amount": 50.0,
            "unit": "mg"
          }
        ],
        "sourceText": "IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. • Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes prior to the paclitaxel infusion • Cimeti"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Atezolizumab",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity",
        "doseModifications": [
          "Dose management guidelines updated for immune-mediated events",
          "Guidelines for infusion-related reactions and cytokine-release syndrome"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Paclitaxel",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Placebo",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_4",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Tumour assessments will be performed at screening/baseline, approximately every 8 weeks (± 1 week) for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression "
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "controlled study designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-PD-L1 antibody) administered in combination with paclitaxel compared with placebo in combination with "
      },
      {
        "id": "visit_2",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "End of Study",
        "sourceText": "continue until the end of the study (EOS; defined as last patient last visit, or LPLV). In the absence of disease progression, paclitaxel and atezolizumab/placebo may be discontinued for toxicity inde"
      },
      {
        "id": "visit_3",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 4,
        "sourceText": "per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (optional sample; collected if clinically feasible from a new or progressing tumour lesion). Tumour assessments will be performed at scre"
      },
      {
        "id": "visit_5",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Radiographic Disease Progression",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Survival Follow-up",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 12,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_6",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Treatment",
        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
      },
      {
        "id": "visit_8",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Treatment",
        "sourceText": "administered on Day 8 of the cycle, it may be administered on Day 15 if counts have recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of pacli"
      },
      {
        "id": "visit_9",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Treatment",
        "sourceText": "recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of paclitaxel should be administered on Day 1 of the following cycle when ANC and platelets "
      },
      {
        "id": "visit_llm_5",
        "visitName": "Cycle 2, Day 1",
        "targetDay": 29,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 5,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Tumor Assessment (First 12 Months)",
        "targetDay": 56,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 8,
        "epoch": "Treatment"
      },
      {
        "id": "visit_7",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "loss to follow-up, or study termination by the Sponsor. Information regarding PFS2, PROs and the use of subsequent anti-cancer agents for metastatic TNBC will also be collected during the survival fol"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Tumour PD-L1 status",
          "categories": [
            "IC0",
            "IC1/2/3"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior taxane treatment",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Presence of liver metastases",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_4",
          "name": "Region",
          "categories": [
            "North America",
            "Western Europe/Australia",
            "Eastern Europe/Asia Pacific",
            "South America"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": " \nAtezolizumab—F. Hoffmann-La Roche Ltd \n19/Protocol MO39196 (IMpassion131), Version 6.0 \ntumour biopsy sample may be used. Of these additional options, the most recent sample should \nbe used.  \nStudy"
    }
  }
}